Improvement of Organizational Performance of Innovative Drugs Approval in Russia and Eurasian Economic Union

Student: Chaplenko Aleksandr

Educational Programme: Health Care Administration and Economics (Master)

Year of Graduation: 2021

One of the key conditions for the development of the healthcare system is the introduction of innovative drugs with the most favorable benefit-risk ratio into clinical practice. For today, the drug registration system in Russia and the EAEU does not provide measures to support the developers of original drugs, and registration of innovative medicines occurs several years after approval in the United States and the European Union. A comprehensive analysis of the main directions of development, as well as a comparison of Russian and foreign approaches can become the basis for improving the regulatory system in order to increase the availability of modern high-quality, effective and safe drugs for the healthcare systems of Russia and the EAEU.

Student Theses at HSE must be completed in accordance with the University Rules and regulations specified by each educational programme.

Summaries of all theses must be published and made freely available on the HSE website.

The full text of a thesis can be published in open access on the HSE website only if the authoring student (copyright holder) agrees, or, if the thesis was written by a team of students, if all the co-authors (copyright holders) agree. After a thesis is published on the HSE website, it obtains the status of an online publication.

Student theses are objects of copyright and their use is subject to limitations in accordance with the Russian Federation’s law on intellectual property.

In the event that a thesis is quoted or otherwise used, reference to the author’s name and the source of quotation is required.

Search all student theses